These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 16860502)

  • 21. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
    Sharara AI
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography.
    Ekpe A; Jacobsen T
    Drug Dev Ind Pharm; 1999 Sep; 25(9):1057-65. PubMed ID: 10518247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
    Luciani F; Spada M; De Milito A; Molinari A; Rivoltini L; Montinaro A; Marra M; Lugini L; Logozzi M; Lozupone F; Federici C; Iessi E; Parmiani G; Arancia G; Belardelli F; Fais S
    J Natl Cancer Inst; 2004 Nov; 96(22):1702-13. PubMed ID: 15547183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
    Vogt K; Hahn H
    Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversed-phase high performance liquid chromatographic method for the determination of lansoprazole, omeprazole and pantoprazole sodium sesquihydrate in presence of their Acid-induced degradation products.
    El-Sherif ZA; Mohamed AO; El-Bardicy MG; El-Tarras MF
    Chem Pharm Bull (Tokyo); 2006 Jun; 54(6):814-8. PubMed ID: 16755049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyl radical scavenging reactivity of proton pump inhibitors.
    Simon WA; Sturm E; Hartmann HJ; Weser U
    Biochem Pharmacol; 2006 Apr; 71(9):1337-41. PubMed ID: 16494850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reaction of proton pump inhibitors with model peptides results in novel products.
    Watson C; Zhu L; Guan S; Machen TE; Forte JG
    J Pharmacol Sci; 2013; 122(3):213-22. PubMed ID: 23877017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of lysosomal enzyme activities by proton pump inhibitors.
    Liu W; Baker SS; Trinidad J; Burlingame AL; Baker RD; Forte JG; Virtuoso LP; Egilmez NK; Zhu L
    J Gastroenterol; 2013 Dec; 48(12):1343-52. PubMed ID: 23478938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Electrochemical behaviour of pantoprazole].
    Knoth H
    Pharmazie; 2004 Mar; 59(3):231. PubMed ID: 15074600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acido-basic properties of proton pump inhibitors in aqueous solutions.
    Kristl A
    Drug Dev Ind Pharm; 2009 Jan; 35(1):114-7. PubMed ID: 18720145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Slow, spontaneous degradation of lansoprazole, omeprazole and pantoprazole tablets: isolation and structural characterization of the toxic antioxidants 3H-benzimidazole-2-thiones.
    Rajab A; Touma M; Rudler H; Afonso C; Seuleiman M
    Pharmazie; 2013 Sep; 68(9):749-54. PubMed ID: 24147343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Photocatalytic and photoelectrocatalytic degradation of the drug omeprazole on nanocrystalline titania films in alkaline media: Effect of applied electrical bias on degradation and transformation products.
    Tantis I; Bousiakou L; Frontistis Z; Mantzavinos D; Konstantinou I; Antonopoulou M; Karikas GA; Lianos P
    J Hazard Mater; 2015 Aug; 294():57-63. PubMed ID: 25855613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.
    Tian C; Zhu L; Yu D; Cao Z; Kang T; Zhu R
    Chem Biol Drug Des; 2014 May; 83(5):610-21. PubMed ID: 24350826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers.
    Stroyer A; McGinity JW; Leopold CS
    J Pharm Sci; 2006 Jun; 95(6):1342-53. PubMed ID: 16625655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preformulation investigation of the novel proton pump inhibitor lansoprazole.
    Kristl A; Vrecer F
    Drug Dev Ind Pharm; 2000 Jul; 26(7):781-3. PubMed ID: 10872099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.
    Shin JM; Kim N
    J Neurogastroenterol Motil; 2013 Jan; 19(1):25-35. PubMed ID: 23350044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Degradation of omeprazole induced by enteric polymer solutions and aqueous dispersions: HPLC investigations.
    Riedel A; Leopold CS
    Drug Dev Ind Pharm; 2005 Jan; 31(2):151-60. PubMed ID: 15773282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Stability of pantoprazole in parenteral nutrition units].
    Valverde Molina E; González Muñiz V; Gómez-Maldonado J; Muñoz Castillo I
    Farm Hosp; 2008; 32(5):290-2. PubMed ID: 19150045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring the on-line titration of enantiomeric omeprazole employing continuous-flow capillary microcoil 1H NMR spectroscopy.
    Hentschel P; Holtin K; Steinhauser L; Albert K
    Chirality; 2012 Dec; 24(12):1074-6. PubMed ID: 22887745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of the acid-induced degradation products of omeprazole and 5-hydroxyomeprazole by high-resolution mass spectrometry.
    Roberts J; McNaughtan ML; MacLachlan J; Hunter C; Pahl O
    Rapid Commun Mass Spectrom; 2018 Jun; 32(12):929-941. PubMed ID: 29569771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.